Summary
Global Markets Direct’s, ‘Allergan Plc - Product Pipeline Review - 2016’, provides an overview of the Allergan Plc’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Allergan Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Allergan Plc
- The report provides overview of Allergan Plc including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Allergan Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Allergan Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Allergan Plc’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Allergan Plc
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Allergan Plc’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Allergan Plc Snapshot 8
Allergan Plc Overview 8
Key Information 8
Key Facts 8
Allergan Plc - Research and Development Overview 9
Key Therapeutic Areas 9
Allergan Plc - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Partnered Products/Combination Treatment Modalities 17
Pipeline Products - Out-Licensed Products 19
Out-Licensed Products/Combination Treatment Modalities 20
Allergan Plc - Pipeline Products Glance 21
Allergan Plc - Late Stage Pipeline Products 21
Pre-Registration Products/Combination Treatment Modalities 21
Filing rejected/Withdrawn Products/Combination Treatment Modalities 22
Phase III Products/Combination Treatment Modalities 23
Allergan Plc - Clinical Stage Pipeline Products 24
Phase II Products/Combination Treatment Modalities 24
Phase I Products/Combination Treatment Modalities 25
Allergan Plc - Early Stage Pipeline Products 26
IND/CTA Filed Products/Combination Treatment Modalities 26
Preclinical Products/Combination Treatment Modalities 27
Discovery Products/Combination Treatment Modalities 28
Allergan Plc - Drug Profiles 29
eluxadoline 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
(nebivolol + valsartan) 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
dihydroergotamine mesylate 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
norethindrone 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
abicipar pegol 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Aczone X 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AGN-229666 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
bimatoprost SR 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
cariprazine 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
dalbavancin 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
desmopressin acetate 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
onabotulinumtoxin A 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
oxymetazoline hydrochloride 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
sarecycline hydrochloride 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ulipristal acetate 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AGN-195263 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AGN-223575 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ANT-1207 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ANT-1403 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
brimonidine tartrate implant 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
cyclosporine 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
lidocaine hydrochloride 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NRX-1074 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
oxybutynin chloride 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
rapastinel 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ubrogepant 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
udenafil 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AGN-232411 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
MK-8031 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
bezafibrate ER 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
setipiprant 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
AGN-151200 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecule for Glaucoma 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Neurotoxin Program 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Recombinant Proteins for Ophthalmology 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules to Inhibit CGRP Receptor for Migraine 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Allergan Plc - Pipeline Analysis 82
Allergan Plc - Pipeline Products by Target 82
Allergan Plc - Pipeline Products by Route of Administration 85
Allergan Plc - Pipeline Products by Molecule Type 86
Allergan Plc - Pipeline Products by Mechanism of Action 87
Allergan Plc - Recent Pipeline Updates 90
Allergan Plc - Dormant Projects 132
Allergan Plc - Discontinued Pipeline Products 135
Discontinued Pipeline Product Profiles 135
alvameline maleate 135
dapoxetine hydrochloride 135
dexamethasone acetate 135
dexloxiglumide 136
ME-1036 136
memantine hydrochloride 136
neramexane mesylate 136
NRX-1050 136
NRX-20xx 136
onabotulinumtoxin A 137
radiprodil 137
Allergan Plc - Company Statement 138
Allergan Plc - Locations And Subsidiaries 140
Head Office 140
Other Locations & Subsidiaries 140
Appendix 149
Methodology 149
Coverage 149
Secondary Research 149
Primary Research 149
Expert Panel Validation 149
Contact Us 149
Disclaimer 150
List of Tables
Allergan Plc, Key Information 8
Allergan Plc, Key Facts 8
Allergan Plc - Pipeline by Indication, 2016 10
Allergan Plc - Pipeline by Stage of Development, 2016 13
Allergan Plc - Monotherapy Products in Pipeline, 2016 14
Allergan Plc - Combination Treatment Modalities in Pipeline, 2016 15
Allergan Plc - Partnered Products in Pipeline, 2016 16
Allergan Plc - Partnered Products/ Combination Treatment Modalities, 2016 17
Allergan Plc - Out-Licensed Products in Pipeline, 2016 19
Allergan Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016 20
Allergan Plc - Pre-Registration, 2016 21
Allergan Plc - Filing rejected/Withdrawn, 2016 22
Allergan Plc - Phase III, 2016 23
Allergan Plc - Phase II, 2016 24
Allergan Plc - Phase I, 2016 25
Allergan Plc - IND/CTA Filed, 2016 26
Allergan Plc - Preclinical, 2016 27
Allergan Plc - Discovery, 2016 28
Allergan Plc - Pipeline by Target, 2016 82
Allergan Plc - Pipeline by Route of Administration, 2016 85
Allergan Plc - Pipeline by Molecule Type, 2016 86
Allergan Plc - Pipeline Products by Mechanism of Action, 2016 87
Allergan Plc - Recent Pipeline Updates, 2016 90
Allergan Plc - Dormant Developmental Projects,2016 132
Allergan Plc - Discontinued Pipeline Products, 2016 135
Allergan Plc, Subsidiaries 140
List of Figures
Allergan Plc - Pipeline by Top 10 Indication, 2016 10
Allergan Plc - Pipeline by Stage of Development, 2016 13
Allergan Plc - Monotherapy Products in Pipeline, 2016 14
Allergan Plc - Partnered Products in Pipeline, 2016 16
Allergan Plc - Out-Licensed Products in Pipeline, 2016 19
Allergan Plc - Pipeline by Top 10 Target, 2016 82
Allergan Plc - Pipeline by Top 10 Route of Administration, 2016 85
Allergan Plc - Pipeline by Molecule Type, 2016 86
Allergan Plc - Pipeline Products by Top 10 Mechanism of Action, 2016 87
